BofA analyst Jason Gerberry downgraded ProKidney (PROK) to Underperform from Neutral with a price target of $1, down from $3.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PROK:
- Prokidney’s REACT Study: A Promising Step in Diabetes and Kidney Disease Treatment
- Prokidney’s REACT Study: A New Hope for Diabetic Kidney Disease
- ProKidney Approves Key Proposals at Annual Meeting
- ProKidney’s Prospects: Analyst Maintains $3 Price Target Amid Rilparencel Developments and Financial Stability
- ProKidney Corp. Reports Increased Losses Amid Ongoing R&D